Phase I trial aimed to determine the Maximum Tolerable Dose of the BV in combination with ESHAP in relapsed/resistant Hodgkin Lymphona patients and to evaluate response to treatment with BV-ESHAP as salvage regimen prior to autologous stem cell transplantation.

Trial Profile

Phase I trial aimed to determine the Maximum Tolerable Dose of the BV in combination with ESHAP in relapsed/resistant Hodgkin Lymphona patients and to evaluate response to treatment with BV-ESHAP as salvage regimen prior to autologous stem cell transplantation.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Acronyms GELTAMO
  • Most Recent Events

    • 06 Dec 2016 Results assessing efficacy and safety from phase II portion of the study, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Nov 2016 According to Seattle Genetics media release, data will be presented at the 58th American Society of Hematology (ASH) Annual Meeting Dec 2016.
    • 25 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top